The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Joleen Marie Hubbard
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Genentech/Roche (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); Genentech (Inst); Merck (Inst); Senhwa Biosciences (Inst)
 
Bert H. O'Neil
Consulting or Advisory Role - Amgen; Bayer; Genentech/Roche; Lilly/ImClone
Travel, Accommodations, Expenses - Merck KGaA
 
Derek J. Jonker
No Relationships to Disclose
 
Alexander Starodub
Consulting or Advisory Role - Bayer; Sandoz
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz
 
James D. Peyton
No Relationships to Disclose
 
Henry C. Pitot
No Relationships to Disclose
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Ipsen (Inst); Lexicon (Inst); Merrimack (Inst)
Research Funding - Boston Biomedical (Inst); Esanex (Inst); Ipsen (Inst)
 
Benjamin Rolland Nadeau
No Relationships to Disclose
 
John D. Zubkus
No Relationships to Disclose
 
Bamidele Adesunloye
No Relationships to Disclose
 
William Jeffery Edenfield
Speakers' Bureau - Astellas Medivation; Novartis
 
Youzhi Li
Employment - Boston Biomedical
Stock and Other Ownership Interests - Boston Biomedical
Travel, Accommodations, Expenses - Boston Biomedical
 
Wei Li
Employment - Boston Biomedical
Stock and Other Ownership Interests - Boston Biomedical
Travel, Accommodations, Expenses - Boston Biomedical
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Laura Borodyansky
Employment - Boston Biomedical
Travel, Accommodations, Expenses - Boston Biomedical
 
Chiang Li
Employment - Boston Biomedical
Leadership - Boston Biomedical
Stock and Other Ownership Interests - Boston Biomedical
Consulting or Advisory Role - Boston Biomedical
Patents, Royalties, Other Intellectual Property - Boston Biomedical
Travel, Accommodations, Expenses - Boston Biomedical